Optic neuropathy is damage to the optic nerve, the cable of more than one million nerve fibers that carries visual information from your eye to your brain. When those fibers are injured, whether by poor blood flow, inflammation, compression, toxins, or inherited conditions, the result is partial or complete vision loss in the affected eye. The term covers a family of conditions rather than a single disease, and the cause determines how it feels, how fast it progresses, and how well vision can recover.
How the Optic Nerve Gets Damaged
Regardless of the specific cause, optic neuropathy tends to follow a common sequence at the cellular level. The nerve fibers that make up the optic nerve depend on a steady flow of nutrients and signaling molecules traveling in both directions: from the retina toward the brain and from the brain back to the retina. When something disrupts that flow, whether it’s pressure from a tumor, a blood clot, or inflammation, the fibers begin to swell and eventually break down.
At the same time, the optic nerve’s blood supply is delicate. It relies on tiny branches of the arteries behind the eye. Anything that reduces blood flow through those vessels creates pockets of oxygen deprivation, which accelerates nerve fiber death. Over time, damaged fibers lose their protective insulation (a process called demyelination), and if the injury continues long enough, the nerve physically shrinks, a condition known as optic atrophy. At that point, the lost vision is usually permanent.
Ischemic Optic Neuropathy
The most common form in older adults is ischemic optic neuropathy, which happens when blood flow to the optic nerve is suddenly reduced. It comes in two main varieties, and distinguishing between them is critical because one is a medical emergency.
The non-arteritic form (NAION) is the more common of the two. It typically strikes people with cardiovascular risk factors like high blood pressure and diabetes. Vision loss is usually painless, occurs upon waking, and often affects the upper or lower half of the visual field. Initial visual acuity tends to be moderate rather than severe.
The arteritic form (A-AION) is caused by giant cell arteritis, an inflammatory disease of the blood vessels that predominantly affects people over 70. It is far more aggressive. More than half of patients have vision reduced to counting fingers or worse at the time of diagnosis, and about 75% experience eye pain. The hallmark warning signs are new, persistent headache, tenderness of the scalp or temples, jaw pain while chewing, fatigue, fever, and unexplained weight loss. If giant cell arteritis is suspected, high-dose steroids are started immediately, before blood tests or a biopsy of the temporal artery confirm the diagnosis, because waiting even a day risks permanent blindness in one or both eyes.
Optic Neuritis
Optic neuritis is an inflammatory attack on the optic nerve, most often affecting adults between 20 and 50. The classic presentation is pain behind or around the eye that worsens with eye movement (reported in about 90% of cases), followed within days by blurred or dimming vision in one eye. Colors, especially reds, may look washed out. Vision loss ranges widely, from barely noticeable to complete darkness in the affected eye.
The condition is closely linked to multiple sclerosis. About 20% of people eventually diagnosed with MS had optic neuritis as their very first symptom, and roughly half of MS patients experience it at some point during their disease. A brain MRI at the time of the first episode helps gauge future risk: when the scan is normal, the 15-year probability of developing MS is around 25%. When even one inflammatory lesion is visible, that probability jumps to roughly 75%.
Most people with a single episode of optic neuritis recover substantial vision within weeks to months. A landmark trial published in the New England Journal of Medicine found that intravenous steroids speed that recovery and produce slightly better vision at six months compared to no treatment. Interestingly, the same trial showed that oral steroids alone were ineffective and actually increased the rate of repeat episodes (27% over two years, versus 13% in the intravenous group and 15% with placebo).
Toxic and Nutritional Causes
Certain medications, chemicals, and nutritional deficiencies can slowly poison the optic nerve. The damage is usually symmetrical, affecting both eyes, and tends to cause a gradual blurring of central vision along with faded color perception.
Vitamin B12 deficiency is probably the most common nutritional culprit. It can result from pernicious anemia, prior stomach surgery, celiac disease, chronic acid-reflux medication use, heavy alcohol consumption, or (rarely) a strict vegan diet without supplementation. Folate deficiency plays a similar role and is most often seen in people with poor diets, alcohol use disorders, or conditions that demand rapid cell production, such as pregnancy. Copper deficiency, though less common, can follow gastric surgery or, unusually, result from swallowing too much zinc from denture adhesive cream.
Among medications, ethambutol, a drug used to treat tuberculosis, is the most frequently identified cause of toxic optic neuropathy worldwide, with an estimated global incidence of at least 100,000 affected patients. The risk is dose-dependent and rarely appears before two months of use, with a typical onset around seven months. Methanol poisoning, often from home-distilled alcohol, paint solvents, or antifreeze, can cause rapid and devastating optic nerve damage. Heavy tobacco and alcohol use together have long been associated with a slow, bilateral optic neuropathy as well.
Hereditary Optic Neuropathy
Leber hereditary optic neuropathy (LHON) is a genetic condition passed exclusively through the mother via mutations in mitochondrial DNA. Three specific mutations account for about 90% of cases. Because mitochondria are the energy-producing structures inside cells, and the optic nerve has an unusually high energy demand, these mutations leave the nerve vulnerable to degeneration.
LHON typically strikes between ages 15 and 35, though childhood and late-onset (after 65) variants exist. Vision loss usually begins painlessly in one eye, with the second eye following weeks to months later. Central vision deteriorates rapidly, often to a level where reading and recognizing faces becomes impossible, while peripheral vision is generally preserved. Males are affected far more often than females, even when both carry the same mutation, for reasons that are still not fully understood.
What Vision Loss Feels Like
The pattern of vision loss depends on which nerve fibers are damaged. In many forms of optic neuropathy, the central visual field is affected first, creating a blind or dim spot right where you look. This makes reading, driving, and recognizing faces especially difficult. In ischemic optic neuropathy, the loss often follows a horizontal line, wiping out the upper or lower half of your vision in one eye, a pattern called an altitudinal defect.
During acute optic neuritis, roughly two-thirds of patients start with a large central scotoma, a broad area of dimness or darkness that can cover most of the visual field tested in a standard exam. As the condition resolves over the following year, that diffuse loss often contracts into smaller, more localized defects along the natural arc of nerve fiber bundles.
Color vision is frequently affected even when overall sharpness seems reasonable. You might notice that reds appear duller or more orange in the affected eye. This discrepancy between relatively preserved visual acuity and noticeably impaired color vision is a hallmark clue that the problem is in the optic nerve rather than elsewhere in the eye.
How It’s Diagnosed
One of the simplest and most informative tests is the swinging flashlight test. A clinician shines a light alternately into each eye, watching how the pupils respond. In a healthy visual system, both pupils constrict equally regardless of which eye is illuminated. When one optic nerve is damaged, the pupil of the affected eye dilates rather than constricts when the light swings to it, a response called a relative afferent pupillary defect, or RAPD. This quick, non-invasive test can detect optic nerve damage even when visual acuity in both eyes appears similar.
Optical coherence tomography (OCT) provides a cross-sectional scan of the retinal nerve fiber layer at the back of the eye. In a healthy eye, this layer averages about 102 microns in thickness. In eyes with optic nerve damage, that number drops, with glaucomatous eyes, for example, averaging around 91 microns, an 11% reduction. Thinning on OCT confirms that nerve fibers have been lost and helps track whether the damage is progressing over time.
Visual field testing maps blind spots and areas of reduced sensitivity. An MRI of the brain and orbits is typically ordered when optic neuritis or a compressive lesion is suspected. Blood tests for inflammatory markers, vitamin levels, or specific antibodies round out the workup depending on the suspected cause.
Treatment and Outlook
Treatment depends entirely on the underlying cause. For giant cell arteritis, immediate high-dose steroids are the standard, and the goal is to prevent the unaffected eye from losing vision rather than to reverse damage already done. For optic neuritis, intravenous steroids shorten recovery time, and most patients regain functional vision, though subtle deficits in color perception or contrast sensitivity often linger.
Toxic and nutritional optic neuropathies are often partially reversible if the offending substance is removed or the deficiency is corrected early. Stopping ethambutol, for instance, leads to some visual recovery in many patients, especially when the drug hasn’t been used for an extended period. B12 injections can halt and sometimes reverse nerve damage caused by deficiency, particularly when treatment begins before optic atrophy has set in.
For NAION, no treatment has proven consistently effective, and management focuses on controlling the underlying cardiovascular risk factors to protect the other eye. LHON has the poorest visual prognosis overall, though a small percentage of patients, particularly those with one specific mutation, experience some spontaneous improvement months to years after onset. A gene therapy approved in some countries targets the most common LHON mutation, though long-term outcomes are still being evaluated.
Across all types, the single most important factor in preserving vision is how quickly the cause is identified. Optic nerve fibers that have fully degenerated cannot regenerate, so the window for intervention is defined by how much nerve remains intact at the time of diagnosis.